272 related articles for article (PubMed ID: 22094931)
1. Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2012 Feb; 124(2):250-3. PubMed ID: 22094931
[TBL] [Abstract][Full Text] [Related]
2. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.
Wolfberg AJ; Berkowitz RS; Goldstein DP; Feltmate C; Lieberman E
Obstet Gynecol; 2005 Sep; 106(3):548-52. PubMed ID: 16135585
[TBL] [Abstract][Full Text] [Related]
3. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH
Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
[TBL] [Abstract][Full Text] [Related]
4. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
[TBL] [Abstract][Full Text] [Related]
5. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies.
Growdon WB; Wolfberg AJ; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
J Reprod Med; 2006 Nov; 51(11):871-4. PubMed ID: 17165432
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].
Geng S; Feng FZ; Xiang Y; Wan XR; Zhou Y
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):24-7. PubMed ID: 21429430
[TBL] [Abstract][Full Text] [Related]
7. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
[TBL] [Abstract][Full Text] [Related]
8. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
[TBL] [Abstract][Full Text] [Related]
9. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type.
Schmitt C; Doret M; Massardier J; Hajri T; Schott AM; Raudrant D; Golfier F
Gynecol Oncol; 2013 Jul; 130(1):86-9. PubMed ID: 23523617
[TBL] [Abstract][Full Text] [Related]
10. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
[TBL] [Abstract][Full Text] [Related]
11. A Novel Prediction Model for Postmolar Gestational Trophoblastic Neoplasia and Comparison With Existing Models.
Zhao P; Wang S; Zhang X; Lu W
Int J Gynecol Cancer; 2017 Jun; 27(5):1028-1034. PubMed ID: 28498254
[TBL] [Abstract][Full Text] [Related]
12. Postmolar gestational trophoblastic neoplasia: beyond the traditional risk factors.
Bakhtiyari M; Mirzamoradi M; Kimyaiee P; Aghaie A; Mansournia MA; Ashrafi-Vand S; Sarfjoo FS
Fertil Steril; 2015 Sep; 104(3):649-54. PubMed ID: 26099850
[TBL] [Abstract][Full Text] [Related]
13. Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level.
Gueye M; Kane-Gueye SM; Ndiaye-Gueye MD; Mbaye M; Diouf AA; Niang MM; Diallo M; Moreau JC
BJOG; 2014 Oct; 121(11):1415-9. PubMed ID: 24674295
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of clinical features, human chorionic gonadotropin (hCG) value, and hCG ratios for early prediction of postmolar gestational trophoblastic neoplasia.
Rakprasit C; Ruengkhachorn I; Therasakvichya S; Inthasorn P; Achariyapota V; Kuljarasnont S; Khemworapong K; Jareemit N
Arch Gynecol Obstet; 2023 Apr; 307(4):1145-1154. PubMed ID: 36116082
[TBL] [Abstract][Full Text] [Related]
15. Normal human chorionic gonadotropin regression curves in uneventful postmolar patients.
Kizaki S; Matsui H; Usui H; Shozu M; Hanawa S; Yamamoto E; Kikkawa F
J Reprod Med; 2012; 57(5-6):243-8. PubMed ID: 22696820
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
van Trommel NE; Sweep FC; Schijf CP; Massuger LF; Thomas CM
Eur J Endocrinol; 2005 Oct; 153(4):565-75. PubMed ID: 16189178
[TBL] [Abstract][Full Text] [Related]
17. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
[TBL] [Abstract][Full Text] [Related]
18. The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles.
Baasanjav B; Usui H; Kihara M; Kaku H; Nakada E; Tate S; Mitsuhashi A; Matsui H; Shozu M
Hum Reprod; 2010 May; 25(5):1183-91. PubMed ID: 20208060
[TBL] [Abstract][Full Text] [Related]
19. Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve.
van Cromvoirt SM; Thomas CM; Quinn MA; McNally OM; Bekkers RL
Gynecol Oncol; 2014 Jun; 133(3):542-5. PubMed ID: 24631700
[TBL] [Abstract][Full Text] [Related]
20. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
